***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND most disease-modifying therapies ( DMTs ) for multiple sclerosis ( MS ) are self-injectable medications that must be taken on an ongoing basis to reduce disease activity . Thus , adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy . This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing-remitting MS . METHODS this was an observational , multicenter , multinational , phase 4 study . Patients and physicians received paper question naires regarding adherence to DMTs approved at the time of the study , including intramuscular interferon beta-1a ( IFNβ-1a ) , subcutaneous IFNβ-1a , IFNβ-1b , and glatiramer acetate . Quality of life and cognition data also were collected . Multivariate analysis was conducted to identify factors associated with adherence to long-term DMTs . RESULTS two thous and six hundred and forty-eight patients were studied , revealing an average treatment duration of 31 months . Seventy-five percent of patients ( n = 1923 ) were adherent to therapy . The most common reasons for non-adherence were forgetting to administer the injection ( 50.2 % ) and other injection-related reasons ( 32.0 % ) . Adherent patients reported better quality of life ( P < 0.05 ) and fewer neuropsychological issues ( P < 0.001 ) than non-adherent patients . Adherent patients had significantly shorter duration of disease ( P < 0.001 ) and shorter duration of therapy ( P = 0.005 ) than non-adherent patients . Women were more likely than men to adhere to treatment . CONCLUSION identifying factors that affect adherence to prescribed treatments is the first step in improving adherence of patients with MS to therapy , thereby helping maximize the benefits of long-term DMTs 
    Output:
    
Teriflunomide 7 or 14 mg alone had potential benefits on reducing relapse rates , and alone or with add-on IFN-β was safe for patients with relapsing forms of MS in the short term .
Short-term teriflunomide , 7 or 14 mg alone or with add-on IFN-β , was safe for patients with relapsing MS .
Both teriflunomide 7 and 14 mg alone had potential benefits for patients with relapsing forms of MS .